Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1442 of 5804
-
New bladder pain cocktail aims to ease Flare-Ups fast
Symptom relief Recruiting nowThis is a Phase 2, prospective, randomized, double-blind, placebo-controlled, multi-center, single-dose, pharmacodynamic study designed to evaluate the efficacy and safety of the combination product (VNX001) versus placebo and its individual components (heparin sodium and lidocai…
Phase: PHASE2 • Sponsor: Vaneltix Pharma, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
MS drug may shield eyes from damage, new study hopes to prove
Disease control ENROLLING_BY_INVITATIONThis study aims to assess whether, and the degree to which, ofatumumab modulates or reduces rates of retinal atrophy in people with relapsing-remitting MS (RMS), according to baseline serum neurofilament light chain (sNfL) levels.
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New shot could cut opioid use after bunion surgery
Symptom relief CompletedSubjects receive study drug during bunionectomy and are followed for pain and opioid use, with the hypothesis that those who receive CPL-01 will have less pain and less opioid use than either control arm.
Phase: PHASE3 • Sponsor: Cali Pharmaceuticals LLC • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
AI could spot hidden heart attack risks before It's too late
Knowledge-focused Recruiting nowCoronary artery disease (CAD) is among the leading cause of death and disability. Identification of patients at high risk of cardiovascular events is pivotal. However, current risk stratification based on imaging and known biomarkers is suboptimal. The objective of this proposal …
Sponsor: Centro Cardiologico Monzino • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Magnetic pulses may tame deadly heart storms
Symptom relief Recruiting nowThree-arm randomized clinical trial comparing two strategies of TcMS to sham stimulation in patients with VT storm. The hypothesis of the study is that TcMS will reduce the burden of VT in the 24 hours after randomization compared to sham stimulation and that TcMS with theta burs…
Phase: NA • Sponsor: University of Pennsylvania • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
ChatBot keeps tabs on cancer patients, could cut hospital trips
Symptom relief OngoingEvaluate the feasibility of using a chatbot combined with continuous activity monitoring to proactively identify, appropriately triage and help manage patients' symptoms during cancer treatment Determine whether such an early outpatient clinic-based intervention can decrease rate…
Phase: PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
New hope for AML patients: maintenance chemo combo aims to keep remission going
Disease control Recruiting nowThis is a phase IB/II study with a 3+3 dose de-escalation study design. Patients will continue maintenance treatment with CPX-351 for 6 cycles on D1 and D3, as long as patient remains in CR. The dose de-escalation will be one dose given on D1 only, every 28 days pending toxicity.…
Phase: PHASE1, PHASE2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Keto vs. Low-Fat: which diet helps heart failure patients move better?
Disease control Recruiting nowThis study is being done to evaluate the effects of a low carbohydrate ketogenic diet (KD) versus a low-fat diet (MD) on exercise tolerance in participants with heart failure with normal pumping function and diabetes or pre-diabetes, or metabolic syndrome, or obesity.
Phase: NA • Sponsor: Ohio State University • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug cocktail shows promise for slowing kidney disease
Disease control CompletedThis was a 28-week, open-label, multicenter, single-group Phase 2 exploratory study to determine the safety and effect of sparsentan in participants with IgAN who are at risk of disease progression to kidney failure despite being on both stable RAASi and SGLT2 inhibitor treatment…
Phase: PHASE2 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Experimental 'Alarm' therapy aims to rev up immune system against Hard-to-Treat cancers
Disease control Recruiting nowThis is a single center Phase I study with extension of peptide alarm therapy (PAT) administered by intratumoral (IT) injection during the 1st course of a standard of care intravenous PD-1/PD-L1 inhibitor for the treatment of locally advanced or metastatic solid tumor cancers tha…
Phase: PHASE1 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Electric implant aims to restore erections after prostate cancer surgery
Disease control Recruiting nowThe goal of this clinical trial is to assess if a new device is safe to use as a potential treatment for erectile dysfunction following radical prostatectomy. The main questions it aims to answer are: * Is the device safe? * Does the device works well? Are the participants sati…
Phase: NA • Sponsor: Comphya Australia • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Spine surgery breakthrough? bone marrow clot may speed up fusion
Disease control OngoingSpinal fusion (SF) is a common orthopedic procedure to treat spinal diseases. Apart from fixation systems, the procedure requires bone grafting to further improve SF. Cell-based therapies as vertebral bone marrow aspirate (vBMA) with bone allograft were developed as alternative t…
Phase: NA • Sponsor: Istituto Ortopedico Rizzoli • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Ancient acupoint massage meets modern exercise: a new hope for aging muscles and sleep?
Disease control Recruiting nowThe purpose of this study is to evaluate the clinical efficacy and impact of digital/remote courses combining traditional Chinese medicine (TCM) acupoint-stimulated interventions, health education, and exercise on sarcopenia and sleep disturbances across distinct age groups. By i…
Phase: NA • Sponsor: Tainan Hospital, Ministry of Health and Welfare • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New Three-Drug cocktail aims to tackle relapsed lymphoma
Disease control OngoingTo find a recommended dose of valemetostat that can be given in combination with rituximab and lenalidomide to patients with follicular lymphoma. The safety and effects of this drug combination will also be studied
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug duo targets tough lung cancer in early trial
Disease control OngoingThe purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and cetrelimab combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor effect …
Phase: PHASE1, PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug may scratch the itch for dialysis patients
Symptom relief CompletedThis a multicentre study that consists of a 12-week double-blind period, and an optional 14-week open-label extension period and a 1-week follow-up period.
Phase: PHASE3 • Sponsor: Vifor Fresenius Medical Care Renal Pharma • Aim: Symptom relief
Last updated Jun 26, 2026 15:36 UTC
-
Blood test breakthrough? new study hopes to sniff out liver cancer early.
Diagnosis Recruiting nowHIDE (Hepatocellular Carcinoma Identification via Delta-HLD) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, in detecting hepatocellular carcinoma (HCC). The study includes both plasma a…
Sponsor: Epiliquid Holding, Inc • Aim: Diagnosis
Last updated Jun 26, 2026 14:28 UTC
-
AI-Powered daily radiation adjustments aim to improve anal cancer treatment
Disease control Recruiting nowThis is a 20 patient pilot study to examine the feasibility of dose-adapted radiation therapy for the treatment of locally advanced anal squamous cell cancer. The tumor and a patient's anatomy may change during radiation treatment and daily adaption of the radiation plan (i.e., a…
Phase: NA • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug combo aims to control CLL/SLL in early treatment
Disease control OngoingThis phase II trial tests how well tafasitamab and zanubrutinib works in treating patients with newly diagnosed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow an…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New Triple-Drug cocktail aims to tackle tough breast cancer
Disease control Recruiting nowThis phase Ib trial tests the safety and tolerability of ZEN003694 in combination with an immunotherapy drug called pembrolizumab and the usual chemotherapy approach with nab-paclitaxel for the treatment of patients with triple negative-negative breast cancer that has spread to o…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC